Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
$2.47
-5.4%
$3.10
$1.80
$7.93
$108.33M0.17264,632 shs603,783 shs
Immuneering Corporation stock logo
IMRX
Immuneering
$3.39
-5.6%
$2.00
$1.00
$3.87
$124.15M0.382.56 million shs908,546 shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$16.29
+3.5%
$13.45
$10.80
$17.79
$236.39M-0.0495,352 shs53,380 shs
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$2.14
+0.6%
$1.81
$1.07
$4.62
$229.36M0.36659,483 shs175,653 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.00%+11.26%-14.53%-26.92%+246,999,900.00%
Immuneering Corporation stock logo
IMRX
Immuneering
0.00%-3.97%+65.37%+140.43%+200.00%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
0.00%+12.86%+26.34%+22.08%+21.17%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
0.00%+5.05%+19.72%+81.61%+30.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
1.2477 of 5 stars
3.70.00.00.00.90.00.0
Immuneering Corporation stock logo
IMRX
Immuneering
4.0924 of 5 stars
3.34.00.00.04.25.00.6
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.1931 of 5 stars
0.01.00.04.60.02.51.3
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
2.1281 of 5 stars
3.63.00.00.02.90.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
3.40
Buy$12.67412.82% Upside
Immuneering Corporation stock logo
IMRX
Immuneering
2.60
Moderate Buy$13.25290.86% Upside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.00
HoldN/AN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
3.13
Buy$8.00273.31% Upside

Current Analyst Ratings Breakdown

Latest IMRX, INBX, PRQR, and HURA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$8.00
6/27/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$8.00
6/23/2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/5/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
5/16/2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
5/15/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/13/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.00
5/7/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/A$0.34 per shareN/A
Immuneering Corporation stock logo
IMRX
Immuneering
$320K381.27N/AN/A$1.33 per share2.55
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$200K1,178.71$116.32 per share0.14$9.23 per share1.76
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$18.97M11.88N/AN/A$0.91 per share2.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$21.68MN/A0.00N/AN/A291.69%122.09%N/A
Immuneering Corporation stock logo
IMRX
Immuneering
-$61.04M-$1.96N/AN/AN/AN/A-119.22%-99.22%8/5/2025 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.69B$116.750.14N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$30.04M-$0.35N/AN/AN/A-157.04%-53.49%-22.07%8/4/2025 (Estimated)

Latest IMRX, INBX, PRQR, and HURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$0.13-$0.15-$0.02-$0.15N/AN/A
5/14/2025Q4 2024
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.55-$2.80-$0.25-$2.80N/AN/A
5/8/2025Q1 2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 million
5/5/2025Q1 2025
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.41-$0.42-$0.01-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/AN/A
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A
3.00
3.00
Immuneering Corporation stock logo
IMRX
Immuneering
N/A
7.48
7.48
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.04
5.12
5.12
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.62%
Immuneering Corporation stock logo
IMRX
Immuneering
67.65%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
32.65%

Insider Ownership

CompanyInsider Ownership
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.20%
Immuneering Corporation stock logo
IMRX
Immuneering
22.90%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
17.09%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A43.68 million43.59 millionN/A
Immuneering Corporation stock logo
IMRX
Immuneering
6035.99 million27.75 millionNot Optionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.48 million12.00 millionOptionable
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
180105.21 million96.38 millionOptionable

Recent News About These Companies

PRQR - ProQR Therapeutics NV Sustainability - Morningstar
ProQR Therapeutics N.V. (PRQR) - Yahoo Finance
Cantor Fitzgerald Comments on PRQR FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

TuHURA Biosciences stock logo

TuHURA Biosciences NASDAQ:HURA

$2.47 -0.14 (-5.36%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$2.49 +0.02 (+0.81%)
As of 07/3/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Immuneering stock logo

Immuneering NASDAQ:IMRX

$3.39 -0.20 (-5.57%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$3.38 -0.02 (-0.44%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$16.28 +0.55 (+3.46%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

ProQR Therapeutics stock logo

ProQR Therapeutics NASDAQ:PRQR

$2.14 +0.01 (+0.52%)
As of 07/3/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.